Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) championing the missions that help people live better and healthier lives. Every product that Catalent helps develop, manufacture and launch reflects its commitment to improve health outcomes around the world through its Patient First approach. Catalent provides unparalleled service to pharma, biotech and consumer health customers, delivering on their missions to transform lives. Catalent tailors end-to-end solutions to meet customers’ needs in all phases of development and manufacturing. With thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually.
Trish Hunt,
Group Vice President & Chief Marketing Officer
Trish Hunt currently serves as Group Vice President & Chief Marketing Officer at Catalent, Inc., a leading global CDMO.
Since joining Catalent in 2011, Ms. Hunt has served in a variety of roles of increasing responsibility including VP, Business Development Nutritionals & Beauty; Global VP, Softgel & Oral Technologies; and President, Consumer Health.
In addition to her tenure at Catalent, Ms. Hunt has over 20 years of progressive operational and leadership experience holding various roles across different industries from Fortune 500 companies including The Disney Company and JPMorganChase.
Ms. Hunt holds a bachelor’s in hospitality management from Niagara University, and a master’s in organizational leadership from Pfeiffer University.
Q&A with Trish Hunt
Why does participating as an Investor in the Tampa Bay EDC make sense for Catalent?
Catalent champions the missions that matter—those that help people live better and healthier lives. Our strong presence in the Tampa Bay region reflects our commitment to innovation and growth, and investing in the Tampa Bay Economic Development Council (EDC) is a natural extension of that commitment. Tampa offers us a vibrant and growing healthcare and innovation hub, which allows us to easily expand capabilities, attract top talent, and drive advancements that improve patient outcomes. By supporting the EDC, Catalent helps strengthen the region as a hub for business, talent, and healthcare innovation. This investment will help build on the strong foundation established by the EDC and further enhance an ecosystem where life-changing therapies can thrive, benefiting patients and communities locally and globally.
Since Catalent currently has a catalog of 1,000 products, what is the pharmaceutical or biopharmaceutical product that is the most unique?
Catalent partners with innovators of all sizes—biotech, pharma, and consumer health—to bring forward therapies that transform lives. Among the most unique are those developed for rare diseases, where treatment options are limited or nonexistent. Catalent supports pioneering programs such as gene therapies for rare diseases like Duchenne Muscular Dystrophy and new mechanisms to treat cancer, which represent breakthroughs for patient populations with urgent unmet needs. These programs are enabled by Catalent’s advanced technologies and end-to-end expertise, which allow us to overcome complex development and manufacturing challenges. Our role as an innovator of delivery technologies and multi-modality manufacturing platforms ensures that bold ideas become therapies that matter.
What will Catalent’s presence in Tampa Bay look like a decade from now?
Catalent’s vision for Tampa Bay is one of continued growth and leadership. We see the region evolving into an even stronger healthcare and innovation hub, where Catalent will be at the forefront, strengthening our business, driving innovation, investing in our people – all with the goal of improving patient outcomes. Our commitment to the community and to our customers means we will continue to invest in infrastructure, technology, and people, ensuring that Tampa Bay remains integral to Catalent’s global network and to the future of health.
